Evaluation of the effect of butyrate supplementation on the expression of circadian genes, inflammation, sleep quality and psychological factors in patients with ulcerative colitis

Ulcerative colitis (UC) is a type of inflammatory bowel disease (IBD). Although its prevalence is rapidly rising worldwide, the pathophysiology and definite treatment of IBD is yet unknown. In particular, Canada is among countries with the highest IBD prevalence. Recently, circadian rhythm disruption has received significant interest for the IBD pathophysiology. In addition IBD patients develop dysbiosis, associated with a decreased number of the gut bacteria producing butyrate. Lately, there has been growing evidence of butyrate therapeutic approaches in the IBD management. Butyrate potentially exerts an epigenetic control on circadian rhythms by regulation of circadian genes, and can improve dysbiosis. However, there is no study on the effect of butyrate therapy on the circadian genes expression in UC patients. This study aims to investigate the effect of butyrate therapy in such patients on regulating the circadian genes expression, improving clinical symptoms, inflammation and sleep quality, and reducing stress and depression incidents.

Faculty Supervisor:

Aurélie Labbe

Student:

Partner:

Shiraz University of Medical Sciences

Discipline:

Life Sciences

Sector:

Health and Related Sciences & Technology; Pharmaceuticals; Agriculture and Food

University:

HEC Montréal

Program: